GLP-1 Maintenance: What Happens After Goal Weight, Whether You Can Keep Treatment at a Lower BMI, and Switching Providers Near Goal

Maintenance is the longest part

A patient who starts tirzepatide or semaglutide spends four to six months titrating and another six to twelve losing weight, then, if things go well, faces a question that lasts for years: what now? The trials answered the medical part of that question clearly. The commercial part — what providers offer maintenance patients, and what it costs — is less well documented, and it is where maintenance patients have the most leverage.

What the withdrawal trials showed

SURMOUNT-4 (JAMA, 2024) enrolled 783 adults with obesity, gave everyone tirzepatide for 36 weeks (mean loss 20.9%), then randomized them to continue tirzepatide or switch to placebo for 52 weeks. The continuers lost a further 5.5%, for a total of about 25.3% from baseline. The placebo group regained 14.0%, recovering roughly two-thirds of what they had lost, and their cardiometabolic improvements reversed in parallel. Nearly 90% of continuers maintained at least 80% of their initial loss; about 17% of the placebo group did.

STEP 4 (JAMA, 2021) ran the same design with semaglutide: 20 weeks of run-in to 2.4 mg, then continuation or placebo for 48 weeks. Continuers lost a further 7.9%; the placebo group regained 6.9%. The STEP 1 extension followed participants for a year after the trial ended and treatment stopped: they regained about two-thirds of lost weight, and blood pressure, lipids and HbA1c returned toward baseline.

The conclusion is not that the drugs fail. It is that obesity behaves like hypertension or diabetes: the treatment works while it is taken. Weight-management guidelines from the Obesity Medicine Association and others now describe obesity as a chronic disease requiring long-term management, and the FDA labels for Zepbound and Wegovy are for "chronic weight management" for this reason.

What maintenance can look like

Maintenance is provider-directed ongoing care. It is not a guarantee of a particular medication at a particular dose forever, and no telehealth provider can honestly promise that, because the clinician reviews the patient at each renewal and circumstances change. Within that, there are three common approaches.

Continue the effective dose. This is what the trials tested and what the evidence supports. A patient who reached goal on 10 mg tirzepatide continues 10 mg weekly. Appetite suppression persists, weight is stable, and the cardiometabolic benefits hold.

Reduce the dose. Many clinicians step maintenance patients down — from 15 mg to 10 or 7.5 mg, or from 2.4 mg semaglutide to 1.7 mg — and some patients hold their weight at a lower dose with fewer side effects and lower cost at dose-based providers. There is no randomized trial of dose reduction for maintenance; it is an individualized decision informed by the patient's response, and the label's maintenance doses for tirzepatide (5, 10 or 15 mg) give room for it.

Extend the interval. Dosing every 10 or 14 days rather than weekly is also practiced and also untested in trials. Given the five- to seven-day half-lives, trough levels fall considerably on a two-week interval, and some patients notice appetite returning in the second week. It is a clinical judgment.

Lifestyle work matters more in maintenance than at any other stage: resistance training and protein to preserve lean mass (our guide), regular weighing to catch regain early, and a plan for what happens if weight starts to climb.

Eligibility after you have lost the weight

A recurring worry on sales calls is that a patient who started at BMI 34 and is now at BMI 26 will be told they no longer qualify. In general, that is not how it works. The FDA label criteria (BMI ≥30, or ≥27 with a weight-related condition) describe who may start treatment; continued treatment is a clinical decision about the condition being treated, and a BMI reduced by successful treatment is the outcome, not a disqualification. Telehealth providers' intake forms sometimes apply the starting criteria mechanically, so a transferring maintenance patient should supply their starting weight and history, not just their current weight, and expect the clinician — not the form — to make the call.

Insurance is different. Some plans require re-authorization and apply BMI criteria at renewal; a patient on brand-name medication through insurance may find coverage ends after reaching a lower BMI. That is one reason maintenance patients on brand medication sometimes move to cash-pay options.

Switching providers in maintenance

Maintenance patients are, in cost terms, the ideal switchers. They know their dose, so they can compare providers on the single number that matters — the all-in price at that dose — and ignore starting-dose promotions. They know their tolerability, so a 12-month term at a locked rate is a small risk rather than a gamble. And they have documentation: a year of labels, dose history and weights.

The comparison usually favors flat-rate, all-inclusive plans. A maintenance patient on 10 mg tirzepatide at a dose-based provider is paying a mid-to-high tier plus membership every month — using Mochi Health's reported figures, well above $200 — against $139 on NexLife's 12-month plan or $169 month-to-month, at the same dose, with a stated price lock and a policy that a patient who leaves can return at the same rate. That last provision matters specifically for maintenance patients, who may want to pause and resume. Our switching guide covers documentation and timing, and the cheapest tirzepatide ranking is ordered on maintenance-dose totals.

What to ask a prospective maintenance provider: Do you offer a lower-dose or maintenance plan, and at what price? Can I pause and return, and at what rate? How often does the clinician review maintenance patients? What happens to my plan if I need to stop for surgery or pregnancy planning?

Regain: catching it early

Trial data suggest regain after stopping is fast, but regain while continuing is slow and usually manageable. A maintenance plan should include weekly weighing, a threshold (many clinicians use 3-5% above the maintenance weight) at which the patient and clinician revisit dose and lifestyle, and honesty about the fact that appetite creeps back at lower doses or longer intervals. Patients who reduced their dose and regained can usually re-titrate; patients who stopped entirely face the SURMOUNT-4 curve.

The bottom line

Reaching goal weight is the beginning of maintenance, not the end of treatment. The evidence favors continuing; the options for how are individualized; eligibility is generally not lost by succeeding; and the cost of maintenance is the cost a patient will pay longest, which makes it the price worth negotiating hardest — and the one at which flat-rate plans are almost always cheapest.

Sources

1. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48
2. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021;325:1414-1425
3. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553-1564
4. Zepbound and Wegovy prescribing information
5. Obesity Medicine Association, Obesity Algorithm 2024, chronic disease model of obesity treatment

Citations are to primary sources (peer-reviewed trials, FDA labeling and announcements, and provider pricing pages). See our sources policy and corrections log.